[HTML][HTML] Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis
A Domnich, C de Waure - International Journal of Infectious Diseases, 2022 - Elsevier
Objectives MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal
influenza vaccines have been developed to protect the elderly at high risk of severe …
influenza vaccines have been developed to protect the elderly at high risk of severe …
[HTML][HTML] Relative vaccine effectiveness of adjuvanted trivalent influenza vaccine over three consecutive influenza seasons in the United States
C Boikos, I McGovern, JR Ortiz, J Puig-Barberà… - Vaccines, 2022 - mdpi.com
Traditional influenza vaccines may be less immunogenic in adults≥ 65 years of age due to
immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated …
immunosenescence. Two influenza vaccines—MF59®-adjuvanted trivalent inactivated …
[HTML][HTML] Comparative Effectiveness of Bivalent (Original/Omicron BA. 4/BA. 5) COVID-19 Vaccines in Adults
H Kopel, VH Nguyen, C Boileau, A Bogdanov, I Winer… - Vaccines, 2023 - mdpi.com
The emergence of Omicron variants coincided with declining vaccine-induced protection
against SARS-CoV-2. Two bivalent mRNA vaccines, mRNA-1273.222 (Moderna) and …
against SARS-CoV-2. Two bivalent mRNA vaccines, mRNA-1273.222 (Moderna) and …
[HTML][HTML] An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older …
A Fochesato, S Sottile, A Pugliese, S Márquez-Peláez… - Vaccines, 2022 - mdpi.com
Standard-dose quadrivalent influenza vaccines (QIV) are designed to provide protection
against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ …
against all four influenza strains. Adjuvanted QIV (aQIV), indicated for individuals aged 65+ …
Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory …
M Imran, J Puig‐Barbera, JR Ortiz… - Influenza and Other …, 2024 - Wiley Online Library
Background Adults≥ 65 years of age have suboptimal influenza vaccination responses
compared to younger adults due to age‐related immunosenescence. Two vaccines were …
compared to younger adults due to age‐related immunosenescence. Two vaccines were …
[HTML][HTML] The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
SI Pelton, JF Mould-Quevedo, VH Nguyen - Vaccines, 2023 - mdpi.com
Influenza can exacerbate underlying medical conditions. In this study, we modelled the
potential impact of an egg-based quadrivalent influenza vaccine (QIVe) or adjuvanted QIV …
potential impact of an egg-based quadrivalent influenza vaccine (QIVe) or adjuvanted QIV …
[HTML][HTML] Weiterentwickelte zielgruppenorientierte Influenzaimpfstoffe–Neue Evidenz zeigt höhere Effektivität bei älteren Erwachsenen
M Frühwein, J Schelling, K Wahle… - DMW-Deutsche …, 2023 - thieme-connect.com
Die saisonale Influenza verursacht eine signifikante Krankheitslast in der deutschen
Bevölkerung und geht mit hohen volkswirtschaftlichen Kosten einher. Personen ab 60 …
Bevölkerung und geht mit hohen volkswirtschaftlichen Kosten einher. Personen ab 60 …
Additional Burden Averted in the United States From Use of MF59-Adjuvanted Seasonal Influenza Vaccine Compared With Standard Seasonal Influenza Vaccine …
I McGovern, A Sardesai, A Taylor… - Open Forum …, 2023 - academic.oup.com
Background The MF59-adjuvanted trivalent inactivated influenza vaccine (aIIV3) is designed
to overcome immunosenescence and enhance vaccine responses in older adults. We …
to overcome immunosenescence and enhance vaccine responses in older adults. We …
Efficacy, effectiveness and safety of the adjuvanted influenza vaccine in the population aged 65 or over
AM MP, P Rubió, J Puig-Barberà… - Revista Espanola de …, 2023 - europepmc.org
La mayoría de las complicaciones y fallecimientos relacionados con la gripe estacional
ocurren en población de 65 años o más y con enfermedades de base, y la vacuna frente a …
ocurren en población de 65 años o más y con enfermedades de base, y la vacuna frente a …
Impact de la vaccination répétée sur l'efficacité de terrain du vaccin antigrippal de 2018-2019: une étude de cohorte rétrospective
P Doyon-Plourde - 2023 - papyrus.bib.umontreal.ca
Bien qu'il s' agisse d'une maladie évitable par la vaccination, la grippe cause annuellement
environ 3 à 5 millions de cas de maladie grave et environ 290 000 à 650 000 décès dans le …
environ 3 à 5 millions de cas de maladie grave et environ 290 000 à 650 000 décès dans le …